Autoantibody predicts survival of patients with hepatocellular carcinoma
2024
Okayama University Graduate School of Medicine, Okayama, Japan
This study investigated serum anti-PD-1 autoantibody levels as potential biomarkers for predicting the efficacy of atezolizumab and bevacizumab combination therapy (Atezo/Bev) in advanced hepatocellular carcinoma (HCC) patients. In a prospective study of 63 patients, serum anti-PD-1 autoantibody levels were measured before treatment. While not significantly associated with treatment response overall, higher antibody levels correlated with worse overall survival rates in first-line therapy patients. The antibody titer was identified as an independent risk factor for poor prognosis, along with higher neutrophil-to-lymphocyte ratio and lower albumin levels. These findings suggest that serum anti-PD-1 autoantibody levels may serve as a biomarker for predicting immune checkpoint inhibitor efficacy in HCC patients.
Anti-PD-1 autoantibody predicts survival of patients with hepatocellular carcinoma receiving atezolizumab/bevacizumab
Akinobu Takaki
Added on: 12-03-2024
[1] https://www.sciencedirect.com/science/article/pii/S2772572324001134[2] https://www.drugtargetreview.com/news/153350/anti-pd-1-autoantibody-a-biomarker-candidate-for-hcc
